1.Real-world effectiveness and safety of upadacitinib in difficult-to-treat Crohn's disease: a multicenter study in China
Zile ZHANG ; Shuowen ZHANG ; Wensong GE ; Yue LI ; Ruidong CHEN ; Wen TANG ; Qunying WANG ; Yihong FAN ; Linyan ZHOU ; Feng TIAN ; Chunxiao CHEN ; Yubei GU ; Duowu ZOU
Chinese Journal of Inflammatory Bowel Diseases 2025;09(6):443-447
Objective:To evaluate the efficacy and safety of upadacitinib in the real-world treatment of difficult-to-treat Crohn's disease (DTT-CD) .Methods:This multicenter, retrospective cohort study included patients diagnosed with DTT-CD according to the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) criteria, and treated at eight Chinese inflammatory bowel disease centers between January 2023 and March 2025. Clinical outcomes were assessed after 12 weeks of induction therapy with upadacitinib (45 mg qd), including clinical remission rate, clinical response rate, and incidence of adverse events.Results:Among 151 enrolled DTT-CD patients, the clinical remission rate was 47.0%, and the clinical response rate was 90.7% after 12 weeks of treatment. Adverse events occurred in 42 cases (27.8%) .Conclusion:Upadacitinib demonstrated favorable efficacy in inducing clinical remission in DTT-CD patients, with a good safety profile at the induction dose (45 mg qd) .
2.Effect and safety of auricular composite tissue particle injection in treatment of flat nose
Jianmiao FANG ; Xiang YAO ; Yihong GU
Chinese Journal of Medical Aesthetics and Cosmetology 2025;31(3):269-274
Objective:To investigate the efficacy and safety of auricular composite tissue particle injection in the treatment of nasal collapse.Methods:Patients with flat nose in Yuyao People′s Hospital of Zhejiang Province from June 2021 to June 2023 were retrospectively enrolled, and were divided into two groups according to the treatment methods: Observation group, 41 cases were treated with ear complex tissue granule injection, including 16 males and 25 females, aged 19-45 (27.2±1.6) years; Control group, 54 cases underwent silicone prosthesis implantation, including 21 males and 33 females, aged 18-46 (26.4±1.8) years. The satisfaction rates of nasal tip and nasal shape at 1 week, 6 months and 1 year after surgery were compared between the two groups, and the effect maintenance rates of patients at 6 months and 1 year after surgery were compared between the two groups, and the occurrence of adverse reactions in the two groups was recorded.Results:The satisfaction rates of nasal tip at 1 week, 6 months, and 1 year after surgery were 79.6% (43/54), 64.8% (35/54), and 48.2% (26/54) in the control group, and 92.7% (38/41), 78.1% (32/41), and 63.4% (26/41) in the observation group, respectively, and the difference was not statistically significant (all P>0.05). The satisfaction rates of nasal shape at 1 week, 6 months and 1 year after surgery were 79.6% (43/54), 55.6% (30/54) and 40.7% (22/54) in the control group and 90.2% (37/41), 75.6% (31/41) and 56.1% (23/41) in the observation group, respectively, and the difference was not statistically significant (all P>0.05). There was no significant difference in the effect maintenance rate between the two groups at 6 months and 1 year after surgery (all P>0.05). The total incidence of adverse reactions in the observation group was 4.9% (2/41), which was lower than that of 27.8% (15/54) in the control group ( P=0.004). Conclusion:Compared with silicone implantation, there is no significant difference in the nasal tip, nasal shape satisfaction rate and effect maintenance rate of the auricular composite tissue particle injection in the treatment of flat nose , and the incidence of adverse reactions is low.
3.Influence of occupational hazard factors on incidence of hypertension in calcium carbide plant: Historical cohort study
Meng LIU ; Wei ZHANG ; Qi ZHUANG ; Xingyu PENG ; Jinling LIU ; Tiantian CHEN ; Hongmei GU ; Shu GUO
Journal of Environmental and Occupational Medicine 2025;42(5):565-570
Background The high work intensity and possible subsequently increased susceptibility to occupational hazards of calcium carbide plants may lead to hypertension in workers, but there are few studies on the relationship between occupational hazard exposure and hypertension in workers involving the production process of calcium carbide. Objective To explore the influence of occupational hazards on the incidence of hypertension in calcium carbide plants. Methods Using historical cohort design, the employees of a calcium carbide factory in the western part of Inner Mongolia Autonomous Region were selected as research subjects. According to the pre-determined inclusion and exclusion criteria, the study population comprised an exposure group of 377 employees (including furnace workers, inspection workers, and maintenance workers) exposed to dust, noise & carbon monoxide, and a control group of 388 employees (including central control workers, electricians, and administrative personnel) without above-mentioned exposure. The total sample size was 765 participants. The follow-up period was from April 2011 to October 2022, and the study endpoint was defined as the conclusion of the follow-up period or diagnosed hypertension in annual occupational health examination. Information on general demographic characteristics, living habits, and work status was collected from all study subjects. Cox proportional hazards regression model was used to analyze the association between occupational hazard exposure and the risk of hypertension among the calcium carbide plant employees. Results The average age, mean systolic and diastolic blood pressure, proportion of males, smoking rate, and alcohol consumption rate in the exposure group were higher than those in the control group (P<0.05). Compared to baseline, both systolic and diastolic blood pressure levels increased in the exposure group and the control group at the end of the follow-up (P<0.05). At the end of the follow-up, the average differences between systolic/ diastolic blood pressure and baseline values in the exposure group were higher than those in the control group (P<0.05). During the follow-up period, a total of 223 cases of hypertension occurred, with a total follow-up of
4.Real-world effectiveness and safety of upadacitinib in difficult-to-treat Crohn's disease: a multicenter study in China
Zile ZHANG ; Shuowen ZHANG ; Wensong GE ; Yue LI ; Ruidong CHEN ; Wen TANG ; Qunying WANG ; Yihong FAN ; Linyan ZHOU ; Feng TIAN ; Chunxiao CHEN ; Yubei GU ; Duowu ZOU
Chinese Journal of Inflammatory Bowel Diseases 2025;09(6):443-447
Objective:To evaluate the efficacy and safety of upadacitinib in the real-world treatment of difficult-to-treat Crohn's disease (DTT-CD) .Methods:This multicenter, retrospective cohort study included patients diagnosed with DTT-CD according to the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) criteria, and treated at eight Chinese inflammatory bowel disease centers between January 2023 and March 2025. Clinical outcomes were assessed after 12 weeks of induction therapy with upadacitinib (45 mg qd), including clinical remission rate, clinical response rate, and incidence of adverse events.Results:Among 151 enrolled DTT-CD patients, the clinical remission rate was 47.0%, and the clinical response rate was 90.7% after 12 weeks of treatment. Adverse events occurred in 42 cases (27.8%) .Conclusion:Upadacitinib demonstrated favorable efficacy in inducing clinical remission in DTT-CD patients, with a good safety profile at the induction dose (45 mg qd) .
5.Effect and safety of auricular composite tissue particle injection in treatment of flat nose
Jianmiao FANG ; Xiang YAO ; Yihong GU
Chinese Journal of Medical Aesthetics and Cosmetology 2025;31(3):269-274
Objective:To investigate the efficacy and safety of auricular composite tissue particle injection in the treatment of nasal collapse.Methods:Patients with flat nose in Yuyao People′s Hospital of Zhejiang Province from June 2021 to June 2023 were retrospectively enrolled, and were divided into two groups according to the treatment methods: Observation group, 41 cases were treated with ear complex tissue granule injection, including 16 males and 25 females, aged 19-45 (27.2±1.6) years; Control group, 54 cases underwent silicone prosthesis implantation, including 21 males and 33 females, aged 18-46 (26.4±1.8) years. The satisfaction rates of nasal tip and nasal shape at 1 week, 6 months and 1 year after surgery were compared between the two groups, and the effect maintenance rates of patients at 6 months and 1 year after surgery were compared between the two groups, and the occurrence of adverse reactions in the two groups was recorded.Results:The satisfaction rates of nasal tip at 1 week, 6 months, and 1 year after surgery were 79.6% (43/54), 64.8% (35/54), and 48.2% (26/54) in the control group, and 92.7% (38/41), 78.1% (32/41), and 63.4% (26/41) in the observation group, respectively, and the difference was not statistically significant (all P>0.05). The satisfaction rates of nasal shape at 1 week, 6 months and 1 year after surgery were 79.6% (43/54), 55.6% (30/54) and 40.7% (22/54) in the control group and 90.2% (37/41), 75.6% (31/41) and 56.1% (23/41) in the observation group, respectively, and the difference was not statistically significant (all P>0.05). There was no significant difference in the effect maintenance rate between the two groups at 6 months and 1 year after surgery (all P>0.05). The total incidence of adverse reactions in the observation group was 4.9% (2/41), which was lower than that of 27.8% (15/54) in the control group ( P=0.004). Conclusion:Compared with silicone implantation, there is no significant difference in the nasal tip, nasal shape satisfaction rate and effect maintenance rate of the auricular composite tissue particle injection in the treatment of flat nose , and the incidence of adverse reactions is low.
6.Research progresses on acute skin failure in children
Xi YIN ; Fei CHANG ; Jie CHEN ; Lijuan GU ; Yihong GE ; Jiamin MAO
Chinese Journal of Burns 2024;40(4):395-400
Acute skin failure (ASF) is an inevitable damage to the skin and subcutaneous tissue caused by hemodynamic instability and/or low perfusion. At present, there are some understandings and reports about adult ASF at home and abroad, but there are few reports about children's ASF. This article reviewed the definition, pathophysiological changes, risk factors, clinical manifestations, and management of children's ASF, and put forward suggestions in order to provide ideas for clinical diagnosis and treatment of children's ASF, and promote the further study of children's ASF.
7.Neutrophil-lymphocyte and platelet-lymphocyte ratios for assessing disease activity in patients with rheumatoid arthritis receiving tofacitinib treatment.
Juan TANG ; Juan CHEN ; Guoxin LIN ; Hao ZHANG ; Ming GUI ; Nannan LI ; Yihong GU ; Linjuan LUO ; Jian SUN
Journal of Southern Medical University 2023;43(10):1651-1656
OBJECTIVE:
To evaluate the value of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for assessing disease activity in patients with rheumatoid arthritis (RA) treated with tofacitinib.
METHODS:
This retrospective study was conducted among 98 RA patients in active stage treated with tofacitinib in Third Xiangya Hospital and 100 healthy control subjects from the Health Management Center of the hospital from 2019 to 2021. We collected blood samples from all the participants for measurement of erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6) and other blood parameters 1 month before and 6 months after tofacitinib treatment. We further evaluated PLR and NLR before and after tofacitinib treatment in the RA patients, and analyzed their correlations with RA disease activity.
RESULTS:
PLR and NLR increased significantly in RA patients as compared with the healthy controls. In the RA patients, PLR and NLR were positively correlated with the levels of hs- CRP, ESR, IL- 6, Disease Activity Score of 28 joints-ESR (DAS28-ESR), anti-cyclic citrullinated peptide (CCP), and rheumatoid factor (RF) before and after tofacitinib treatment. Tofacitinib treatment for 6 months significantly decreased hs-CRP, ESR, IL-6, CCP, RF and DAS28-ESR levels in the RA patients.
CONCLUSION
NLR and PLR can be useful biomarkers for assessing disease activity in RA patients treated with tofacitinib.
Humans
;
Neutrophils
;
Retrospective Studies
;
C-Reactive Protein/analysis*
;
Interleukin-6/metabolism*
;
Arthritis, Rheumatoid
;
Lymphocytes
8.Clinical features and survival analysis in non-M 3 acute myeloid leukemia patients with ASXL1 gene mutation
Wenbo JIA ; Jinting LIU ; Xinyu YANG ; Hanyang WU ; Yihong WEI ; Can CAN ; Ruiqing WANG ; Na HE ; Chaoyang GU ; Daoxin MA ; Chunyan JI
Chinese Journal of Hematology 2022;43(10):833-840
Objective:To examine the survival rates and clinical characteristics of people with newly discovered non-M 3 acute myeloid leukemia (AML) who carry the ASXL1 gene mutation. Methods:From January 2016 to April 2021, the clinical information of patients with newly diagnosed non-M 3 AML at Shandong University's Qilu Hospital was retrospectively examined, and their clinical characteristics and survival were compared and analyzed. Gene mutation was detected by next-generation sequencing. Results:① The study included 256 AML patients who were initially diagnosed and had complete data, including 47 cases of ASXL1 gene mutation-positive (ASXL1 +) patients and 209 cases of ASXL1 gene mutation-negative (ASXL1 -) patients. All patients were divided into three groups: elderly (≥60 years old, n=92) , middle-aged (45-59 years old, n=92) , and young (≤44 years old, n=72) . ②WBC, and age were higher in patients with ASXL1 mutations compared to ASXL1 - patients, while complete response after the first round of treatment (CR 1) was lower ( P<0.05) . In the elderly group, WBC and the proportion of aberrant cells in nuclear cells in ASXL1 + patients were higher than those in ASXL1 - patients ( P<0.05) . In the young group, the WBC of ASXL1 + patients was higher than that of ASXL1 - patients ( z=-2.314, P=0.021) . ③IDH2 mutation and ASXL1 mutation was related ( P=0.018, r=0.34) . In ASXL1 + patients, the proportion of peripheral blasts in the high VAF group (VAF>40% ) was higher than that in the low VAF group (VAF<20% ) , and the proportion of aberrant nuclear cells was higher in the duplication and replacement mutation patients than in the deletion mutation patients ( P<0.05) . ④The overall survival (OS) and progression-free survival (PFS) of ASXL1 + patients were shorter than those of ASXL1 - patients (median, 10 months vs 20 months, 10 months vs 17 months; P<0.05) . The proportion number of aberrant cells in nuclear cells (≥20% ) , complex karyotypes, and TET2 mutation were all independent risk variables that had an impact on the prognosis of ASXL1 + patients, according to multivariate analysis ( P<0.05) . Conclusion:ASXL1-mutated non-M 3 AML patients have higher WBC in peripheral blood, a higher proportion of aberrant cells in nuclear cells, lower CR 1 rate, and shorter OS and PFS. Additionally, a poor prognosis is linked to higher VAF, duplication, and substitution mutations in the ASXL1 gene, as well as the high proportion of aberrant cells in nuclear cells, complex karyotype, and TET2 mutation.
9.Expert consensus on the management of diabetic patients with cardiovascular diseases
Yihong SUN ; Kang CHEN ; Xin CHEN ; Weijun GU ; Yuanlin GUO ; Yijun LI ; Tong LIU ; Daoquan PENG ; Yiming MU ; Changsheng MA
Chinese Journal of Internal Medicine 2021;60(5):421-437
Diabetes is the most important comorbidity of cardiovascular disease, and cardiovascular disease is the main cause of mortality and disability of patients with type 2 diabetes. In order to standardize the diagnosis and treatment of patients with diabetes and cardiovascular disease, the National Health Commission Capacity Building and Continuing Education Center organized the experts from the field of cardiology and endocrinology systematically reviewing the research progresses and expert experiences of relevant disciplines from home and abroad, and formulated this consensus. This consensus covers the diagnosis, drug treatment, and risk factor management for patients with diabetes and cardiovascular disease (including atherosclerotic cardiovascular disease and heart failure) from the perspective of cardiovascular disease and diabetes management aiming to strengthen the comprehensive management of patients and ultimately to improve the prognosis of patients. The management of cardiovascular diseases mainly includes the management of blood pressure, blood lipids, anti-thrombosis, anti-myocardial ischemia, anti-ventricular remodeling and so on. Diabetes management mainly includes lifestyle intervention (including diet, exercise, weight loss, etc.), anti-hyperglycemia therapy (including drugs and insulin), blood glucose monitoring, and hypoglycemic prevention. In addition, specific clinical recommendations are given to patients with special health care needs such as diabetic nephropathy, elderly (>75 years), and cardiovascular critical illness.

Result Analysis
Print
Save
E-mail